Effects of verapamil and sodium cromoglycate on bronchoconstriction induced by isocapnic hyperventilation.
Twenty-four patients who were known to develop bronchoconstriction in response to isocapnic hyperventilation (IH) took part in a double-blind, placebo-controlled trial to assess the effects of verapamil (5 mg) and sodium cromoglycate (SCG) 20 mg in the prevention of IH-induced bronchoconstriction. Both drug and placebo were inhaled in dry powder form and responses were assessed by serial measurements of forced expiratory volume in 1 sec (FEV1). Sodium cromoglycate was shown to offer significant protection whereas verapamil powder provoked bronchoconstriction in over 40% of patients and these patients appeared to be those with more marked degrees of bronchial reactivity.
D001250:Asthma, Exercise-Induced / Q000188:drug therapy; D001986:Bronchial Spasm / Q000188:drug therapy*; D004205:Cromolyn Sodium / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006985:Hyperventilation / Q000150:complications*; D008297:Male; D008407:Mast Cells / Q000187:drug effects; D014700:Verapamil / Q000494:pharmacology* / Q000627:therapeutic use
D014700:Verapamil; D004205:Cromolyn Sodium